

Celsion Corporation Investor Relations Department 997 Lenox Drive Suite 100 Lawrenceville, NJ 08648 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: CLSN	
Last Trade:	1.56
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.03 🕇 (+1.961%)
Day Range	1.52 - 1.56
52-Week Range	1.24 - 18.21
Volume	158,111

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Celsion Corporation is an oncology drug development company focused on the development of efficient, effective, and targeted therapies for the treatment of cancer. Founded in 1985, the company has developed elegant therapeutic approaches that deliver high concentrations of widely used anti-cancer agents directly to the tumor site, maximizing efficacy while minimizing the sideeffects of systemic treatments, with the goal of improving patient outcomes in underserved cancer indications. The foundation for this research is a heatsensitive liposomal nanoparticle licensed from Duke Universit... (more)

Stock Performance



Press Releases [View all]

Aug 24, 2017

Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference

Aug 15, 2017

Celsion Corporation Reports Second Quarter
2017 Financial Results and Provides
Business Update

Aug 8, 2017

Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017

Aug 7, 2017

Data Monitoring Committee Completes Mid-Study Review of Celsion's Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer

Aug 4, 2017

Celsion Corporation to Delist from the Tel Aviv Stock Exchange

Financials [View all]

Second Quarter Financial Results

Mar 24, 2017

Annual Report (10-K)

Apr 4, 2017

Proxy Statement (DEF 14A)

Aug 14, 2017

Quarterly Report (10-Q)

May 12, 2017

Quarterly Report (10-Q)

Nov 10, 2016

Quarterly Report (10-Q)